Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor ADC and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for B7-H4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | B7-H4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1 EU/µg, HEK293 Expressed. Sequence Verified. |
View B7-H4 Products |
| Gene Delivery | B7-H4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Native membrane topology preserved. |
View B7-H4 Products |
| Benchmark Ab | Anti-B7-H4 (Clinical Benchmark Sequence, e.g., AZD8205 or GSK4381562 biosimilar) Recombinant positive control for assay calibration. |
View B7-H4 Products |
| Validator | B7-H4 siRNA Set For knockdown verification and specificity controls. |
View B7-H4 Products |
| Related Target A | B7-H3 (CD276) Synergistic B7-family immune checkpoint axis for combination screening. |
View B7-H3 Products |
| Related Target B | PD-L1 (CD274) Central combination target and compensatory resistance pathway. |
View PD-L1 Products |
| Related Target C | TROP2 (TACSTD2) Alternative pan-cancer ADC target for multi-specific rational design. |
View TROP2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation for Toxicology | Human, Mouse, and Cynomolgus B7-H4 ortholog proteins available. High purity (>95%), Sequence Verified. |
| B7 subfamily counter-screening | B7-H3 and B7-H4 homolog panel strictly verified by mass spec. Endotoxin controlled. |
| ADC internalization & feasibility | High-purity ECD-Fc and full-length lentivirus for FACS and imaging internalization assays. Native glycosylation (HEK293) preserves conformational epitopes. |
| Lack of positive controls | Clinical benchmark antibody (biosimilar-grade) included for assay calibration. |
| False positives / off-target binding | Validated siRNA included for target-specificity confirmation in cell-based assays. |
Live B7-H4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for B7-H4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and bispecific formats, including T-cell engagers. B7-H4's restricted tumor expression profile (high in breast, ovarian, endometrial, and lung cancers) and role as a negative immune regulator make it an attractive target for solid malignancies, particularly gynecological cancers. As first-generation therapies advance through early-phase clinics, the next wave of R&D is targeting combination regimens with PD-1/PD-L1 axis blockade and next-generation payload mechanisms. Bispecific platforms (e.g., B7-H4 x CD3 or B7-H4 x 4-1BB) are also being pursued to maximize anti-tumor immunity while minimizing bystander toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Hengrui, BioNTech/DualityBio, AstraZeneca, GSK, Seagen/Pfizer | Breast, Ovarian, Endometrial | Internalization Assay (Need high-purity ECD-Fc and lentivirus-stable cell lines) |
| Bispecific | Multiple Global Biotech Platforms (Genmab, Xencor) | Solid Tumors (Refractory) | Heterodimer Validation (Need cross-reactive Abs and dual-antigen panels) |
| Monoclonal Ab | Multiple Global Biotechs | Solid Tumors | Blocking / ADCC Assay (Need conformationally correct antigen) |
| CAR-T / Cell Therapy | Academic & Industry Programs, Early Stage Biotech | Gynecological Cancers | Cell-based binding & killing (Need lentivirus for stable target cell construction) |
Molecular Differentiation & Assay Strategy
To develop a Best-in-Class B7-H4 therapeutic, molecular design must address affinity, internalization efficiency, safety, and mechanism of action. For ADC modality, internalization rate is the primary differentiating factor; antibodies with moderate-to-high affinity but rapid endocytosis are preferred. pH-sensitive binding (e.g., faster dissociation at endosomal pH 5.5) can enhance payload release. Native glycosylation (HEK293-expressed) is critical for preserving conformational epitopes. Cross-species reactivity (human, cynomolgus, mouse) must be thoroughly assessed to support toxicology studies. Soluble B7-H4 (sB7-H4) competitively binds antibodies, reducing tumor exposure; hence, epitopes that avoid sB7-H4 interference are advantageous. TarMart provides a comprehensive suite of high-purity antigens, benchmark antibodies, and lentiviral constructs to support all these assays.